T cells can acquire a broad spectrum of differentiation states following activation. At the
extreme ends of this continuum are short-lived cells equipped with effector machinery and …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Improvements in tumor immunotherapies depend on better understanding of the anti-tumor
T cell response. By studying human tumor-draining lymph nodes (TDLNs), we found that …

Neutrophils accumulate in solid tumors, and their abundance correlates with poor prognosis.
Neutrophils are not homogeneous, however, and could play different roles in cancer …

Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers,
but the immunological mechanism and molecular determinants of primary and acquired …

Local environmental factors influence CD8+ T cell priming in lymph nodes (LNs). Here, we
sought to understand how factors unique to the tumor-draining mediastinal LN (mLN) impact …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is
treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune …

Myeloid cells are known to suppress antitumour immunity. However, the molecular drivers of
immunosuppressive myeloid cell states are not well defined. Here we used single-cell RNA …

Abstract Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first
FDA-approved immunotherapies and remains a standard treatment for bladder cancer …